How Much Does Trulicity Cost in California in 2026?

Retail and Cash-Pay Pricing Across California

The sticker price for Trulicity in California sits at $931 per month for a single once-weekly pen, matching Eli Lilly's national wholesale acquisition cost. That figure applies whether you fill at a CVS in Los Angeles, a Walgreens in San Francisco, or an independent pharmacy in Sacramento.

Cash-pay patients face the full list price unless they use a discount program. Pharmacy benefit managers negotiate rebates with Eli Lilly, but those savings flow to insurers and plan sponsors rather than uninsured individuals paying out of pocket. The practical result: a California resident without coverage will pay roughly $11,172 per year for brand-name Trulicity.

Price variation between pharmacies does exist, though it is narrow. GoodRx and similar aggregator tools may show prices ranging from $880 to $950 depending on location and pharmacy chain, but the savings compared to list price are modest. No generic dulaglutide is available in the United States as of May 2026, which limits competitive pricing pressure. The REWIND trial (N=9,901) established dulaglutide's cardiovascular benefit in type 2 diabetes patients with and without established cardiovascular disease, reducing major adverse cardiovascular events by 12% over a median 5.4 years of follow-up 1. That evidence base supports formulary inclusion across most California payers, but it does not reduce the out-of-pocket burden for uninsured patients.

A 2023 analysis in Diabetes Care found that GLP-1 receptor agonist adherence drops by 30% when monthly out-of-pocket costs exceed $50 2. California patients paying full cash price face a cost barrier well above that threshold.

Medi-Cal Coverage for Trulicity

Medi-Cal, California's Medicaid program, covers Trulicity for type 2 diabetes with prior authorization. The PA requirement is not a denial. It is a documentation step.

To obtain approval, the prescribing clinician must demonstrate that the patient has a confirmed type 2 diabetes diagnosis, has tried or has a contraindication to metformin, and has an A1C above the plan's threshold (typically 7.0% or higher despite first-line therapy). Medi-Cal managed care plans in California, including L.A. Care, Health Net, and CalOptima, each maintain their own formulary tiers and step-therapy protocols, so the specific documentation requirements may differ slightly by plan.

Once approved, most Medi-Cal beneficiaries pay $0 to $3.80 per prescription. The prior authorization process typically takes 48 to 72 hours. Denials can be appealed, and the American Diabetes Association's Standards of Medical Care provide clinical justification that strengthens appeal letters 3. Dr. Robert Gabbay, Chief Scientific and Medical Officer of the American Diabetes Association, has stated: "Access to GLP-1 receptor agonists should not be limited by administrative barriers when clinical evidence supports their use in a given patient."

For dual-eligible patients (those enrolled in both Medicare and Medi-Cal), Medicare Part D serves as the primary payer. The Inflation Reduction Act's $2,000 annual out-of-pocket cap on Part D spending, fully effective as of 2025, applies to Trulicity and can substantially reduce costs for this population 4.

Commercial Insurance and Employer Plans

Most large commercial insurers in California place Trulicity on a preferred or non-preferred specialty tier. Coverage details vary, but the pattern is consistent across the state's major carriers.

Blue Shield of California and Anthem Blue Cross both cover Trulicity, typically on Tier 3 (preferred brand). Copays for Tier 3 drugs on these plans generally range from $40 to $75 per month for HMO products and $50 to $150 for PPO plans. Kaiser Permanente, which covers approximately 8.9 million Californians, includes dulaglutide on its formulary with step-therapy requirements. Kaiser patients usually must trial metformin and possibly a sulfonylurea or SGLT2 inhibitor before GLP-1 RA authorization.

The Endocrine Society's 2024 clinical practice guideline recommends GLP-1 receptor agonists as second-line therapy after metformin for patients with type 2 diabetes and established atherosclerotic cardiovascular disease, and as an option for those with high cardiovascular risk regardless of A1C level 5. This recommendation strengthens the case for coverage approval when submitting prior authorization to California insurers.

Employer-sponsored plans through Covered California (the state's ACA marketplace) must cover at least one GLP-1 receptor agonist per the essential health benefits mandate. However, "at least one" does not guarantee Trulicity specifically. Some marketplace plans prefer semaglutide (Ozempic) or tirzepatide (Mounjaro) over dulaglutide, requiring a formulary exception for Trulicity.

The Eli Lilly Savings Card Program

Eli Lilly's Trulicity Savings Card offers eligible commercially insured patients a copay as low as $25 per month, with a maximum annual benefit of $6,000. The program runs continuously and does not require income verification.

Eligibility rules are straightforward but exclude certain groups. You qualify if you have commercial or private insurance that covers Trulicity, you are a U.S. resident age 18 or older, and you are not enrolled in a government-funded program (Medicare, Medicaid, Tricare, VA). California patients on Medi-Cal or Medicare Part D cannot use the savings card due to federal anti-kickback statute restrictions.

Activation happens at the pharmacy counter or through the Lilly website. The card applies at the point of sale, reducing your copay in real time. For a California patient whose insurer charges a $150 monthly copay for Trulicity, the savings card would reduce that to $25, saving $1,500 per year.

One limitation: the $6,000 annual cap. A patient whose plan assigns Trulicity a coinsurance rate of 30% (roughly $279 per fill at list price) would exhaust the card's benefit within approximately 21 fills, or about five months. Patients in high-deductible health plans face this scenario more frequently. The AWARD-11 dose-response trial demonstrated that Trulicity 3.0 mg and 4.5 mg doses produced A1C reductions of 1.5% and 1.8%, respectively, compared to 1.4% for the 1.5 mg dose 6. Higher doses cost the same per pen but may improve clinical outcomes, making the savings card even more relevant for patients titrating upward.

Compounded Dulaglutide in California

Compounded dulaglutide is available in California through licensed 503A compounding pharmacies. The California State Board of Pharmacy oversees these facilities under both state law and federal guidance from the FDA's Drug Quality and Security Act.

A 503A pharmacy compounds medications based on a valid patient-specific prescription. These pharmacies do not need to use commercially available products as source material; they may compound from bulk pharmaceutical ingredients when the prescriber determines that a compounded version is medically necessary. The FDA's Drug Quality and Security Act (DQSA) provides the federal framework for 503A operations 7.

Pricing for compounded dulaglutide from California 503A pharmacies varies widely. Some telehealth-affiliated compounders advertise prices as low as $150 to $350 per month, a significant discount from the $931 brand-name list price. Patients should verify that any compounding pharmacy holds a valid California Board of Pharmacy license and that the facility has passed its most recent inspection.

A key distinction: compounded dulaglutide is not FDA-approved. It has not undergone the same bioequivalence testing as brand-name Trulicity. The FDA has issued multiple warning letters to compounding pharmacies producing GLP-1 receptor agonists without adequate quality controls 8. Patients should discuss the risk-benefit profile with their prescriber before switching from brand to compounded product.

Telehealth Prescribing of Trulicity in California

California permits telehealth prescribing of Trulicity with no in-person visit requirement. The state's telehealth parity laws, codified under California Business and Professions Code Section 2290.5, allow licensed physicians, nurse practitioners, and physician assistants to prescribe controlled and non-controlled medications via video or audio-only visits.

Dulaglutide is not a controlled substance, which simplifies the prescribing pathway. A California-licensed provider can evaluate a patient, order labs (A1C, renal function, lipid panel), review results, and prescribe Trulicity entirely through a telehealth platform. Several national telehealth companies and California-based practices offer this service, often bundling the consultation with pharmacy fulfillment.

Telehealth does not change the drug's cost. Patients still face the same $931 list price, the same insurance copays, and the same savings card eligibility. What telehealth does change is access: a patient in rural Kern County or the Inland Empire can receive a prescription without driving hours to an endocrinologist. The CDC reports that 7.3% of California adults have diagnosed diabetes, representing approximately 2.3 million people 9. Many reside in areas designated as Health Professional Shortage Areas, where telehealth fills a genuine gap in specialty care.

How to Lower Your Trulicity Cost in California

Several strategies can reduce out-of-pocket costs depending on your insurance status. The right approach depends on your coverage type.

Commercially insured patients: Activate the Eli Lilly Savings Card first. If your copay exceeds $25 per month even after the card, ask your pharmacy benefit manager whether Trulicity sits on a preferred tier. If not, your prescriber can submit a formulary exception request citing the ADA Standards of Care or the REWIND cardiovascular data 1.

Medi-Cal patients: Your prescriber handles the prior authorization. If denied, file an appeal within 60 days. Include documentation of metformin intolerance or failure, your most recent A1C, and a letter citing guideline recommendations.

Uninsured patients: Eli Lilly's Lilly Cares Foundation provides free Trulicity to qualifying uninsured patients with household income at or below 400% of the federal poverty level. The application requires proof of income, a prescription, and a prescriber signature. Processing takes 4 to 6 weeks. California's Medi-Cal expansion covers adults with incomes up to 138% FPL, so many uninsured patients may qualify for Medi-Cal enrollment instead.

Medicare Part D patients: The $2,000 annual out-of-pocket cap limits total yearly spending across all Part D drugs, including Trulicity. Medicare's Extra Help (Low-Income Subsidy) program further reduces costs for beneficiaries with limited income and resources 10.

A cost-effectiveness analysis published in Annals of Internal Medicine found that GLP-1 receptor agonists meet conventional willingness-to-pay thresholds ($100,000 per QALY) for patients with type 2 diabetes and established cardiovascular disease, but exceed those thresholds for patients without cardiovascular risk factors 11. This finding supports targeted use and strengthens insurance appeals for high-risk patients.

California-Specific Discount and Assistance Programs

Beyond the Eli Lilly Savings Card and Lilly Cares, several California-specific programs may reduce costs.

Covered California plans: Marketplace enrollees earning 138% to 400% FPL receive premium subsidies, and many Silver-tier plans offer reduced copays for specialty medications. Enhanced subsidies under the American Rescue Plan remain in effect through 2025, though Congressional renewal for 2026 remains pending.

County indigent care programs: Los Angeles County's My Health LA and similar county programs in San Francisco (Healthy San Francisco) and other jurisdictions provide prescription assistance for undocumented residents who do not qualify for full-scope Medi-Cal.

340B pricing: Patients who receive care at federally qualified health centers (FQHCs) or other 340B-eligible entities in California may access Trulicity at significantly reduced prices. The 340B program requires drug manufacturers to provide outpatient drugs to eligible healthcare organizations at discounted prices. California has over 200 FQHCs, particularly concentrated in underserved areas of the Central Valley and Inland Empire 12.

Pharmacy discount programs: Costco, which operates 134 locations in California, typically offers lower cash-pay prices for brand-name medications than traditional retail chains. No membership is required to use Costco pharmacies in California.

What the Evidence Says About Dulaglutide Value

The clinical evidence supporting dulaglutide's value in type 2 diabetes is anchored by two major trial programs.

The AWARD series (Assessment of Weekly AdministRation of dulaglutide in Diabetes) comprised 11 randomized controlled trials evaluating dulaglutide against placebo and active comparators. AWARD-1 (N=978) demonstrated that dulaglutide 1.5 mg reduced A1C by 1.51% at 26 weeks versus 0.46% for placebo 13. REWIND (N=9,901), the cardiovascular outcomes trial, showed a 12% reduction in the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke (HR 0.88, 95% CI 0.79 to 0.99, P=0.026) over a median 5.4 years 1.

The REWIND population is notable for its generalizability. Only 31% of enrolled patients had established cardiovascular disease at baseline, meaning the majority had cardiovascular risk factors but no prior events. This broadens the applicability of the cardiovascular benefit beyond the populations studied in LEADER (liraglutide) and SUSTAIN-6 (semaglutide), where 81% and 83% of participants had established cardiovascular disease, respectively.

Dr. Hertzel Gerstein, the REWIND principal investigator, noted: "The cardiovascular benefits of dulaglutide extended to a broad range of people with type 2 diabetes, including those who had risk factors but had not yet experienced a cardiovascular event."

For California patients and their prescribers, this evidence supports Trulicity use in a wider diabetes population than some competing GLP-1 receptor agonists, which may strengthen insurance coverage arguments in prior authorization appeals.

Patients should request A1C testing at 3-month intervals after starting Trulicity, with the target of achieving at least a 0.5% reduction by week 12 to confirm therapeutic response.